12:00 AM
 | 
Oct 06, 2004
 |  BC Extra  |  Clinical News

MethylGene starts MG98 Phase II

MethylGene (TSE:MYG) began a two-step Phase II trial of its MG98 plus interferon alpha in patients with metastatic renal cell cancer. The first portion of the trial will evaluate safety, pharmacokinetics and optimal dosing...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >